Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACAM-FLU-A
- Development stage
- Phase 1
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
ACAM-FLU-A is a genetically engineered, recombinant subunit vaccine designed as a “universal” influenza A vaccine. It targets the M2e peptide, a highly conserved extracellular domain of the M2 ion channel present across all influenza A strains. The vaccine is constructed by presenting the M2e peptide on a hepatitis B core protein carrier to enhance immune response. This approach aims to induce broad, strain-independent immunity against influenza A viruses, including those responsible for pandemic influenza. ACAM-FLU-A demonstrated promising safety and immunogenicity in phase 1 clinical studies and provided protection in preclinical (ferret) challenge studies against highly pathogenic H5N1 avian influenza. Its design intends to address the limitations of seasonal flu vaccines that require frequent reformulation due to antigenic drift[1][2][7].
- Brand names
- ACAM-FLU-A
- Other names
- Influenza A vaccine ACAM Flu-ARecombinant M2e influenza-A vaccine ACAM FLU-A
02
Targets
M2e (Influenza A matrix protein 2 ectodomain)
Beyond the preview
Go deeper on ACAM-FLU-A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACAM-FLU-A.